Crohn's Disease Biologic Medication Cost: Humira, Stelara, Skyrizi, and More
Your gastroenterologist just said you need Stelara. You looked it up. The list price is $22,000 per dose — and you need it every 8 weeks. That’s $143,000 a year at sticker price. Before you spiral, here’s the important context: almost no one pays that number. But understanding what you will pay takes some work, and the difference between plans and programs can be $10,000 or more per year.
Crohn’s disease affects approximately 780,000 Americans, according to the Crohn’s & Colitis Foundation’s 2024 data. Biologics — drugs that target specific immune pathways — are now the backbone of moderate-to-severe Crohn’s treatment. They work better than older therapies, but their pricing structure is one of the most complex in all of medicine.
The Major Biologics for Crohn’s Disease and Their List Prices
| Drug | Class | List Price (Per Year) | Biosimilar Available? |
|---|---|---|---|
| Humira (adalimumab) | Anti-TNF | $83,000 | Yes — many biosimilars ~30–50% cheaper |
| Remicade (infliximab) | Anti-TNF (infusion) | $26,000–$52,000 | Yes — Inflectra, Renflexis, Avsola |
| Stelara (ustekinumab) | Anti-IL-12/23 | $143,000–$175,000 | Biosimilars entered market 2024 |
| Skyrizi (risankizumab) | Anti-IL-23 | $150,000–$190,000 | No (still brand-only) |
| Entyvio (vedolizumab) | Anti-integrin (infusion) | $65,000–$85,000 | Biosimilar (Velsipity) approved |
| Rinvoq (upadacitinib) | JAK inhibitor (oral) | $65,000–$72,000 | No |
These are Wholesale Acquisition Cost (WAC) figures — the pharmaceutical company’s list price before any insurance negotiations, rebates, or discounts. The price your insurance actually pays is negotiated and typically 30–60% lower. What matters to you is the net cost after your insurance’s contract plus your own cost-sharing.
What Patients Actually Pay: The Three Scenarios
Scenario 1: Good commercial insurance with a co-pay card
Most patients with employer-sponsored commercial insurance pay their plan’s specialty tier copay — typically $100 to $500 per month — and then use the manufacturer’s co-pay assistance card to cover all or most of that amount. The result: $0 to $100 per month out of pocket.
AbbVie (Humira’s maker) offers myAbbVie Assist; Janssen (Stelara/Skyrizi) offers Janssen CarePath. These programs are specifically designed to make the copay near zero for commercially insured patients.
Scenario 2: High-deductible commercial insurance without co-pay card
Without a co-pay card (or if your plan’s accumulator adjustment program neutralizes it), you may pay your full deductible in January before coverage kicks in. For a specialty drug like Skyrizi, hitting a $4,000 deductible in month one is common.
Scenario 3: Medicare or Medicaid
Co-pay cards are not allowed for Medicare beneficiaries under federal law. Medicare Part D covers most oral biologics; infusions may be covered under Part B. The Medicare out-of-pocket maximum for prescription drugs was capped at $2,000 per year starting January 2025 (Inflation Reduction Act provision) — a significant change for Crohn’s patients on Medicare.
Medicaid typically covers biologics with prior authorization, and patient cost-sharing is very low ($1–$8 per prescription in most states).
The Biosimilar Opportunity: Real Savings on Humira and Stelara
Multiple adalimumab biosimilars (Hadlima, Cyltezo, Hyrimoz, and others) entered the U.S. market in 2023. Some are priced 30–50% below Humira’s list price. Stelara biosimilars entered in 2024. If your insurer has added a biosimilar to formulary as the preferred agent, you may be asked to switch from the brand.
Here’s what to know: biosimilars for FDA-approved biologics are not generics, but they are clinically equivalent by FDA standard. If your GI doctor is comfortable with a switch, accepting a biosimilar can save you real money — especially if the co-pay card you were using for the brand drug isn’t available for the biosimilar. Ask your pharmacist to run a cost comparison between the brand and biosimilar under your specific plan.
Prior Authorization: The First Hurdle
Every biologic for Crohn’s requires prior authorization (PA) from your insurance company. PA criteria typically include:
- Confirmed Crohn’s diagnosis (usually with colonoscopy documentation)
- Failure or contraindication of at least one conventional therapy (usually azathioprine, 6-mercaptopurine, or methotrexate, and often one anti-TNF agent before newer biologics like Skyrizi are approved)
- Active disease documentation (C-reactive protein, fecal calprotectin, imaging, or endoscopy)
The PA process takes 7 to 21 days. If denied, your GI team can appeal with a peer-to-peer review — a direct call between your doctor and the insurance company’s medical reviewer. These appeals are often successful when documentation is thorough.
Infusion vs. Self-Injection: The Cost Difference
Some Crohn’s biologics are given as infusions (Remicade, Entyvio) administered at an infusion center. Others are self-injected at home (Humira, Stelara after the first induction doses, Skyrizi maintenance).
Infusion drugs carry additional infusion facility fees — typically $500 to $2,500 per session — on top of the drug cost. This affects what you pay if you have coinsurance on outpatient services.
Home injectable biologics eliminate the facility fee but require cold storage and training. From a pure cost perspective, self-injectable biologics with co-pay card coverage often result in lower patient out-of-pocket than infusions, where facility coinsurance adds up.
| Drug Type | Drug Cost Component | Facility/Administration Fee | Co-Pay Card Available? |
|---|---|---|---|
| Home injectable (Humira, Skyrizi) | Specialty pharmacy tier | $0 (home use) | Yes (commercial only) |
| IV infusion (Remicade, Entyvio) | Part B or medical benefit | $500–$2,500 per infusion | Yes (commercial only) |
| Oral pill (Rinvoq) | Specialty pharmacy tier | $0 | Yes (commercial only) |
Patient Assistance Programs for Uninsured Patients
If you’re uninsured or your income is below a threshold, every major biologic manufacturer has a free drug program:
- AbbVie myAbbVie Assist (Humira): Free drug for patients under 400% of federal poverty level without insurance
- Janssen CarePath (Stelara, Skyrizi): Free or reduced-cost drug for qualifying patients
- Takeda Together (Entyvio): Free drug program for uninsured/underinsured
- AbbVie/Rinvoq: Similar program for upadacitinib
The Crohn’s & Colitis Foundation (crohnscolitisfoundation.org) also maintains a financial assistance resource directory that includes insurance navigation, foundation co-pay grants (PAN Foundation, HealthWell Foundation), and state pharmaceutical assistance programs.
The surveillance colonoscopies that Crohn’s patients need alongside their biologic therapy add another layer of annual cost. The colonoscopy cost with Crohn’s disease article covers the procedure side of that equation.